Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated